Show simple item record

dc.contributor.authorBeran, Roy
dc.contributor.authorChow-Chuen, J
dc.date.accessioned2020-07-02T00:54:30Z
dc.date.available2020-07-02T00:54:30Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/10072/395073
dc.description.abstractParkinson’s disease (PD) is a chronic, degenerative disease associated with motor complication that progressively affects quality of life and causes significant disability, either related to disease progression or treatment consequences. A number of guidelines provide treatment algorithms for selection of anti-Parkinsonian medications which suggest delaying the introduction of L-dopa due to the development of motor complications following prolonged exposure. This study examines the efficacy of the treatment model, adopted within a single Australian outpatient clinic, for polypharmacy (based on initiating L-dopa and complemented with later introduction of selegiline and subsequently a dopamine agonist and thence entacapone) for the treatment of Parkinson’s disease and to evaluate this approach to patient management. Of 152 patients with PD identified, 40 had been treated between 5 and 20 years and were analysed further to provide sufficient period to determine disease progression and treatment evaluation. Among the 40 long-term patients, 2.5% (1) of patients required a wheelchair and 15% (6) demonstrated motor complications. The majority of patients were coping well with their Parkinson’s disease and reported good quality of life. This study demonstrates that despite accepted guidelines, adopting a treatment algorithm based on early commencement of treatment with L-dopa and maintenance of low dose therapy with polypharmacy, appears beneficial both in the short term and the long-term management of patients with Parkinson’s disease.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherChembio Publishers
dc.publisher.urihttps://chembiopublishers.com/CNNRIJ/volume.php?volumeId=44&issueId=78
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto9
dc.relation.ispartofissue1
dc.relation.ispartofjournalClinical Neuroscience & Neurological Research International Journal
dc.relation.ispartofvolume2
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchcode3209
dc.titleAn independent clinical audit of an alternative treatment paradigm for the management of Parkinson’s Disease.
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationBeran, R; Chow-Chuen, J, An independent clinical audit of an alternative treatment paradigm for the management of Parkinson’s Disease., Clinical Neuroscience & Neurological Research International Journal, 2019, 2 (1), pp. 1-9
dc.date.updated2020-07-02T00:53:24Z
gro.hasfulltextNo Full Text
gro.griffith.authorBeran, Roy G.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record